 Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1991 | 2 | 1 | 3 | | 1992 | 5 | 2 | 7 | | 1993 | 4 | 0 | 4 | | 1994 | 9 | 2 | 11 | | 1995 | 4 | 2 | 6 | | 1996 | 8 | 1 | 9 | | 1997 | 8 | 6 | 14 | | 1998 | 7 | 4 | 11 | | 1999 | 5 | 1 | 6 | | 2000 | 8 | 1 | 9 | | 2001 | 7 | 2 | 9 | | 2002 | 16 | 3 | 19 | | 2003 | 12 | 0 | 12 | | 2004 | 14 | 3 | 17 | | 2005 | 18 | 2 | 20 | | 2006 | 19 | 3 | 22 | | 2007 | 17 | 1 | 18 | | 2008 | 18 | 5 | 23 | | 2009 | 14 | 1 | 15 | | 2010 | 25 | 1 | 26 | | 2011 | 18 | 2 | 20 | | 2012 | 38 | 2 | 40 | | 2013 | 30 | 8 | 38 | | 2014 | 31 | 2 | 33 | | 2015 | 27 | 0 | 27 | | 2016 | 33 | 2 | 35 | | 2017 | 44 | 1 | 45 | | 2018 | 39 | 2 | 41 | | 2019 | 34 | 1 | 35 | | 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020 01; 26(1):47-51.
-
Davies KD, Merrick DT. Skipping Expected Mechanisms of MET-Mediated Oncogenesis. J Thorac Oncol. 2020 01; 15(1):9-11.
-
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):261-270.
-
Ulke HM, Mutze K, Lehmann M, Wagner DE, Heinzelmann K, Günther A, Eickelberg O, Königshoff M. The Oncogene ECT2 Contributes to a Hyperplastic, Proliferative Lung Epithelial Cell Phenotype in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2019 12; 61(6):713-726.
-
Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 12; 17(12):1464-1472.
-
Mahajan AK, Folch E, Musani A. Should Interventional Pulmonologists Take Ownership for Ordering Next-Generation Sequencing and Immunohistochemistries for Patients With Newly Diagnosed Non-Small Cell Lung Cancer? Chest. 2019 12; 156(6):1281-1282.
-
Camidge DR. Next-generation ALK inhibitors: is the median the message? Lancet Respir Med. 2020 01; 8(1):5-7.
-
Patil T, Camidge DR. Untapped potential: recognising CNS opportunities in early oncology drug development. Lancet Oncol. 2019 12; 20(12):1620-1622.
-
Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct; 55(10):641-652.
-
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|